Press release: Vrije Universiteit Brussels installs MILabs new PET-SPECT-CT-MRI platform for nanobody research


Today MILabs announces the installation of its new PET-SPECT-CT-MR preclinical imaging platform at the In Vivo Cellular and Molecular Imaging (ICMI) lab at the University Brussels (VUB) Belgium.

The highly comprehensive imaging platform combines the best PET-SPECT functional imaging capabilities (sub-half-mm SPECT resolution and sub-mm  PET resolution) with high resolution anatomical imaging from an integrated  X-ray CT subsystem and/or a compact cryogen free 1.5 T MRI unit. The new PET-SPECT-CT-MRI platform will significantly expand the imaging capabilities at the VUB In vivo Cellular and Molecular Imaging Lab.

“With this unique PET-SPECT-CT-MR platform we can perform high throughput and validated imaging pharmacokinetics in specific organs as well as the whole body in vivo, very fast and with extreme high accuracy” says Prof. Tony Lahoute, principal investigator at ICMI lab and head of Nuclear Medicine of the university hospital of the Vrije University Brussel. His groundbreaking nanobody research program has resulted already in several compounds for molecular imaging and therapy in disease areas such as oncology, immunology, cardiology and diabetes. The preclinical imaging research at ICMI has been the basis for several clinical trial programs using radiolabeled nanobodies.
“The newly acquired infrastructure will also be used to implement new ideas on image quality and quantitative accuracy of different radiotracers particularly with the unique capabilities for simultaneously measuring multiple tracers across the entire nuclear energy spectrum” continues Prof. Michel Defrise, principal investigator of the ICMI lab.

“The continues efforts by the Flemish government and the Hercules foundation to provide support to research groups and core facilities such as the ICMI lab, enables MILabs to collaborate on innovating her imaging protocols and contributes in this way to the development of new therapies for major diseases” adds Freek Beekman, Ph.D., CEO and founder of MILabs BV.

About the In Vivo Cellular and Molecular Imaging Lab 

At the In Vivo Cellular and Molecular Imaging (ICMI) lab of the University Brussels (VUB), multiple small animal imaging modalities are centralized together with a unit for probe development and a vivarium for the housing of animals. Different research teams collaborate in an interdisciplinary research effort which encompasses the development and validation of innovative core technologies, their applications in preclinical translational research and the introduction of these emerging technologies into clinical diagnostic imaging practice.  For more information see www.icmibrussels.be.

 About MILabs

MILabs provides high-end molecular imaging solutions for biomedical and pharmaceutical research. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. U-SPECT4 provides the fastest, most sensitive and highest resolution small-animal SPECT currently available. Recently MILabs introduced VECTor4 and VECTor4CT providing extremely user friendly, fully integrated and simultaneous ultra-high resolution PET/SPECT with a choice of different low-dose high-resolution CT subsystems. For more information see www.milabs.com.

Share on social media
Share on facebook
Share on twitter
Share on linkedin
Share on email

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a …

Read More →

MILabs announced the co-winners of the MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress …

Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor …

Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting …

Read More →

The University of Southampton enters the field of Correlative In-Vivo Imaging by acquiring MILabs 3D/4D Optical/CT

May 12, 2020, Southampton, UK – Utrecht, the Netherlands The Faculty of Medicine, University of …

Read More →

MILabs remotely installs from the Netherlands new E-Class PET/SPECT/CT at Osaka University of Pharmaceutical Sciences

Osaka, Japan and Utrecht, the Netherlands May 4th, 2020 In a world with COVID-19 travel …

Read More →

University of Torino (UNITO) acquires an advanced MILabs molecular imaging system

The University of Torino (UNITO) acquires advanced MILabs molecular imaging system for the design of …

Read More →

Truman VA acquires VECTor preclinical imaging system featuring exclusive multimodal synergy capabilities.

Columbia, Missouri, USA and Utrecht, the Netherlands April 9th, 2020 Harry S. Truman Memorial Veterans’ …

Read More →

Cyprus-based EPOS-Iasis acquires MILabs innovative Optical/CT system

Aimed at achieving a paradigm shift in Oncology research by imaging and quantifying fluorescent signals …

Read More →

MILabs enhances micro-CT for Coronavirus (COVID-19) research.

March 19, 2020 – Utrecht, the Netherlands Based on recent scientific research, diagnostic X-ray CT …

Read More →

The Julius Wolf Institute at the Charité installs mission-critical MILabs microCT for in-vivo studies of musculoskeletal regeneration

25 February 2020 – Berlin-Germany and Utrecht, Netherlands, The Julius Wolff Institute for Biomechanics and …

Read More →

MILabs realizes a breakthrough in preclinical oncology imaging by eliminating the positron range effect of 89Zr-immunoPET

February 15, 2020 – Utrecht, the Netherlands Researchers at MILabs B.V. have succeeded at imaging …

Read More →
Scroll to Top